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Abstract
Background: Even though the prevalence of HIV infection among the adult population in Ethiopia was estimated
to be 2.2% in 2008, the studies on the pattern of neurological manifestations are rare. The aim of this retrospective
study was to assess the pattern and predictors of mortality of HIV/AIDS patients with neurologic manifestations.
Methods: Medical records of 347 patients (age ≥13 years) admitted to Tikur Anbesa Hospital from September 2002
to August 2009 were reviewed and demographic and clinical data were collected.
Results: Data from 347 patients were analysed. The mean age was 34.6 years. The diagnosis of HIV was made
before current admission in 33.7% and 15.6% were on antiretroviral therapy (ART). Causes of neurological
manifestation were: cerebral toxoplasmosis (36.6%), tuberculous meningitis (22.5%), cryptococcal meningitis (22.2%)
and bacterial meningitis (6.9%). HIV-encephalopathy, primary central nervous system (CNS) lymphoma and
progressive multifocal leukoencephalopathy were rare in our patients. CD4 count was done in 64.6% and 89.7%
had count below 200/mm3[mean = 95.8, median = 57] and 95.7% were stage IV. Neuroimaging was done in 38%
and 56.8% had mass lesion. The overall mortality was 45% and the case-fatality rates were: tuberculous meningitis
(53.8%), cryptococcal meningitis (48.1%), cerebral toxoplasmosiss (44.1%) and bacterial meningitis (33.3%). Change
in sensorium and seizure were predictors of mortality.
Conclusions: CNS opportunistic infections were the major causes of neurological manifestations of HIV/AIDS and
were associated with high mortality and morbidity. Almost all patients had advanced HIV disease at presentation.
Early diagnosis of HIV, prophylaxis and treatment of opportunistic infections, timely ART, and improving laboratory
services are recommended. Mortality was related to change in sensorium and seizure.
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Introduction
Symptomatic neurologic dysfunction develops in more
than 50% of individuals infected with human immuno-
deficiency virus (HIV) [1] and about 10% experience
neurologic symptoms as the initial manifestation of
acquired immunodeficiency syndrome (AIDS) [2]. Neu-
rologic disorders associated with HIV infection include
central nervous system (CNS) infections, neoplasms,
vascular complications, peripheral neuropathies and
myopathies [3]. Neurologic dysfunction is an important
cause or a strong marker of poor prognosis in late HIV
infection [4].
Studies done in developing countries showed that the
major causes of neurologic disorders in HIV/AIDS
patients are CNS opportunistic infections [5-12]. In
Ethiopia, the adult prevalence of HIV infection was esti-
mated to be 2.2% in 2008 [13] but data on the pattern
of neurological complications of HIV/AIDS are rare.
This study was designed to assess the clinical presenta-
t i o n ,c a u s e ,t r e a t m e n t ,o u t c o m ea n dp r e d i c t o r so fm o r -
tality in HIV/AIDS patients with neurological
complications who were admitted to Tikur Anbesa Hos-
pital (TAH), the main teaching hospital of Addis Ababa
University.
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In this retrospective study, HIV infected patients aged ≥
13 years who were admitted with neurological manifes-
tations of HIV/AIDS to TAH from September 2002 to
August 2009 were included. Medical records of patients
were retrieved and data sheets were used to collect the
following data: age, sex, address, occupation, marital sta-
tus, presenting symptoms and signs, investigations,
treatment, duration of hospital stay, treatment outcome
at hospital discharge.
Confidentiality was assured by giving each patient a
unique number. The study was started after getting ethi-
cal approval from the appropriate body of the medical
faculty of the university. Patients excluded from the
study were: patients age < 13 years, patients who were
not admitted, who had wrong diagnosis, or there were
insufficient data for diagnosis.
Clinical staging of HIV/AIDS was made based on
World Health Organization (WHO) staging system for
HIV infection and disease [14]. The most recent CD4
count was taken into consideration. Poor outcome at
hospital discharge was defined as patients who remained
in the same clinical condition or deteriorated without
death. Improved patients were patients who showed par-
tial or complete recovery. The presumptive diagnosis of
the neurological manifestations of HIV/AIDS was made
as follows:
Cerebral toxoplasmosis
Presumed diagnosis based on some or all of the follow-
ing: i) headache, fever, change in sensorium ii) focal
neurologic deficit iii) seropositivity for anti-toxoplasma
immunoglobulin G(IgG), iv) ring enhancing brain lesion
(s) on computerized tomography(CT)/magnetic reso-
nance imaging(MRI), v) low CD4 count(< 200/mm3),
and vi) response to toxoplasma treatment.
Tuberculous meningitis
Based on some or all of the following: i) headache, fever,
neck rigidity, change in mentation ii) cerebrospinal fluid
(CSF) lymphocytosis iii) Acid-fast bacilli(AFB) on CSF
smear iv) evidence of active tuberculosis in other part of
the body (milliary tuberculosis, pulmonary tuberculosis
etc.) v) CT/MRI showing meningeal enhancement vi)
response to tuberculosis treatment.
Tuberculoma
i) headache, change in sensorium ii) focal deficit iii) CT/
MRI contrast enhancing lesion, and iv) response to
tuberculosis treatment.
Cyptococcal meningitis
CSF India ink positivity.
Bacterial meningitis
i) acute onset headache, fever, change in mentation,
neck rigidity ii) CSF polymorph predominant pleocytosis
iii) CSF culture and Gram stain showing bacteria iv)
response to antibiotics.
Neurosyphilis
CSF Venereal Disease Research Laboratory (VDRL) reactive.
Stroke
Sudden onset of neurologic deficit which persisted for >
24 h of presumed vascular origin.
Guillian-Barre syndrome (GBS)/chronic inflammatory
demyelinating polyneuropathy(CIDP)
Progressive weakness, paresthesias, areflexia, high CSF
protein with pleocytosis, evidence of demyelination on
nerve conduction studies.
Primary CNS lymphoma
i) headache, change in sensorium, focal neurologic defi-
c i ti i )l o wC D 4c o u n t( <2 0 0 / m m 3 )i i i )C T / M R Ie n h a n -
cing mass lesion iv) no response to toxoplasmosis and
tuberculosis treatment
Progressive multifocal leukoencephalopathy (PML)
i) multifocal progressive focal deficits, ii) CT/MRI multi-
ple non-enhancing white matter lesions without edema
or mass effect.
Neurocyticercosis
multiple cerebral calcified lesions on CT scan.
HIV encephalopathy
i) cognitive and motor abnormalities ii) CT/MRI showing
brain atrophy iii) other opportunistic infections ruled out.
Pseudotumor cerebri
i) clinical evidence of increased intracranial pressure ii)
normal CT/MRI
The data was analysed using SPSS 13.0 for Windows
(SPSS, Chicago IL, USA). Logistic regression was used
to assess each possible prognostic factor. Odds ratios
and significant levels were calculated along with 95%
confidence interval. A p-value of less than 0.05 was con-
sidered significant. A multivariate logistic regression
analysis was performed to determine which prognostic
factors, when considered together, were the best predic-
tors of hospital death.
Results
Data from 347 patients were analysed. The mean age
was 34.6 years (range 14-65) and 50.7% were males.
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widowed (7.8%), divorced (6.3%) and unknown (2.3%).
The occupation was known for 305(87.9%) patients:
housewives 86(24.8%), office employees 74(21.3%), car
driver 36(10.4%), unemployed 31(8.9%), merchant 28
(8.1%), daily laborer 21(6.1%), student 5(1.4%) and
others 24 (6.9%).
Twenty-five percent (25%) came from outside Addis
Ababa and the mean duration of symptoms was 30.6
days (range 1-240). The mean duration of symptoms for
the major neurologic disorders identified was cerebral
toxoplasmosis (25 days, median 14 days), tuberculous
meningitis (34 days), cryptococcal meningitis (26 days)
and bacterial meningitis (10 days). The diagnosis of HIV
was made in 117 patients before current hospital admis-
sion and there was no statistically significant difference
in case-fatality between patients who were diagnosed
before and after admission (p = 0.315). The mean dura-
tion between diagnosis of HIV and current hospital
admission was known for108 patients, and ranged
between 1 and 120 months (mean 14.8 months). History
of treatment with antiretroviral therapy (ART) was iden-
tified in 54(15.6%) patients with mean duration of treat-
ment of 7.2 months (median 5 months, range1-29).
ART was discontinued before hospital admission in 5
cases (They went to holy water). Co-trimoxazole pro-
phylaxis was given to 15 cases before current admission
and 2(13.3%) of these developed cerebral toxoplasmosis
(p-value = 0.230).
The mean hospital stay was 21.9 days (range1-120).
The mean hospital stay in days for improved and
deceased patients was 26.4 (range 7-120) and 16.9
(range 1-91), respectively. The clinical manifestation of
patients with neurological disorders is shown in Table 1
and the neurologic manifestation of HIV/AIDS in rela-
tion to outcome status is shown in Table 2. Herpes Zos-
ter scar was identified in 67(19.3%) of cases. Co-
morbidities identified at admission were pulmonary
tuberculosis 18(5.2%) and pneumonia 18(5.2%). Some
patients (n = 7, 2%) had more than one neurologic com-
plications of HIV/AIDS: cryptococcal meningitis and
neurosyphilis (n = 3), cryptococcal meningitis and GBS
(n = 1), neurosyphilis and GBS (n = 1), tuberculous
meningitis and tuberculoma (n = 1), cerebral toxoplas-
mosis and neurosyphilis (n = 1). The Glasgow coma
scale (GCS) was recorded in 85(24.5%) of cases and 35
(41.2%) had score of ≤ 8. The Case-fatality of patients
with GCS score of ≤ 8 and > 8 was not different
(p-value = 0.936). The WHO clinical staging of HIV/
AIDS patients showed that majority (n = 332, 95.7%)
were stage IV and the remaining were stage III (n = 15,
4.3%) cases.
Investigations
CD4 count was done in 224(64.6%) cases and 201
(89.7%) had count of below 200/mm3. The mean and
median CD4 count per mm3 was 95.8 and 57, respec-
tively. The mean CD4 count per mm3 for the major
neurologic disorders identified was: cryptococcal menin-
gitis = 55.5, cerebral toxoplasmosis = 66.3, tuberculous
meningitis = 113.8 and bacterial meningitis = 204.4.
Lumbar puncture was done in 226(65.1%) and the mean
cell count was 467.3(range 1-8400). The mean differen-
tial count of neutrophil and lymphocyte was 39.2%
(range 0-98) and 60.4%(range2-100), respectively. India
ink was done in 216(62.2%) and was positive in 77
(35.6%) cases. Out of 213(61.4%) patients tested for CSF
VDRL, 9(4.2%) cases were reactive. Serology for toxo-
plasmosis (IgG) was done in 65(18.7%) and was positive
in 44(67.7%) patients (titer was not done). CSF Gram
stain and Acid fast stain showed organisms in 2 and 1
cases, respectively. Neuroimaging was done in 132(38%):
CT-scan = 127, CT-scan and MRI = 2 and MRI = 3.
The findings were: mass lesion (abscess and tumor) =
75(56.8%), normal = 30(22.7%), infarction = 13, menin-
geal enhancement = 5, brain atrophy = 5, non-enhan-
cing white matter lesions = 2 and intracerebral
hemorrhage = 2. Of the 75 patients with mass lesion on
neuroimaging 60(80%) cases were diagnosed to have
toxoplasmosis.
Treatment
Toxoplasmosis was treated with sulfadoxine-pyrimetha-
mine [pyrimethamine-sulfadiazine was not available].
Tuberculosis was treated with combination of Isoniazid,
rifampin, pyrazinamide, ethambutol or streptomycine
Table 1 Clinical presentations of HIV/AIDS patients with neurological disorders
Sign/symptom Cerebral toxoplasmosis(127) Tuberculos meningitis(78) Cryptococcal meningitis(77) Bacterial meningitis(24)
Headache(212) 60(47.2%) 51(65.4%) 71(92.2%) 16(66.7%)
Altered sensorium(187) 74(58.3%) 57(73.1%) 28(36.4%) 18(75%)
Meningeal sign(136) 17(13.4%) 45(57.7%) 49(63.6%) 19(79.2)
Seizure(119) 54(42.5%) 27(34.6%) 21(27.3%) 6(25%)
Focal deficit(117) 83(65.4%) 9(11.5%) 5(6.5%) 1(4.2%)
Fever(108) 25(19.7%) 31(39.7%) 30(39%) 14(58.3%)
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with oral fluconazole (n = 45) or Amphotericin B (n =
32). Seizure was treated with phenytoin in almost all
patients. Dexamethasone intravenously was given (n =
182, 52.4%) and prednisolone used in 26(7.5%) cases.
One or more intravenous antibiotics (ceftriaxone, crys-
talline penicillin, gentamycine etc.) was given to 212
(61.1%) cases. ART was started after admission in 135
(70.7% of cases discharged alive).
Outcome
The case-fatality was 45%(n = 156) and the number of
patients with poor outcome (discharged in the same
clinical condition or deteriorated without death) was
6.1%(n = 21). In almost all patients, the immediate
cause of death was attributable to the identified neurolo-
gic disorder(s).
Both univariate and multivar i a t el o g i s t i cr e g r e s s i o n
analysis (Table 3) showed that address from Addis
Ababa, altered sensorium and seizure were predictors of
mortality.
Discussion
The objectives of our study were to assess the clinical
presentation, cause, treatment, outcome and predictors
of mortality in patients with HIV/AIDS with neurologic
complications admitted to the largest referral hospital in
Ethiopia. Both sexes were equally affected unlike other
studies [7,8,10,11] where males outnumbered females.
Majority of our patients were young (mean age 34.6
years) which is similar to other studies [7-11]. There
was delay at presentation (mean duration of symptoms
prior to presentation was 30.6 days). The mean duration
of symptoms prior to presentation for patients with cer-
ebral toxoplasmosis (25 days) and cryptococcal meningi-
tis (26 days) was similar to another study [2]. Majority
(66.3%) of cases were known to have HIV infection after
current hospital admission. Almost all patients had
advanced HIV disease at presentation (4.3% stage III
and 95.7% stage IV) which is consistent with another
study [8].
The occurrence of seizure in cerebral toxoplasmosis in
other studies [2,3] was 25% and 29%, respectively, which
was lower compared to our finding. In another study
[12], seizure occurred in 40% of patients with cerebral
toxoplasmosis which was similar to our study. In a
s t u d y[ 1 2 ]t h eo c c u r r e n c eo fs e i z u r ei nt u b e r c u l o u s
meningitis (28%) and cryptococcal meningitis (50%) was
lower and higher, respectively, compared with findings
in our study. The common neurologic disorders identi-
fied in our cases were: cerebral toxoplasmosis (36.6%),
tuberculous meningitis (22.5%) and cryptococcal menin-
gitis (22.2%), and the frequencies were similar to other
studies [5,6,11,12,15]. In contrary to our findings, tuber-
culous meningitis and bacterial meningitis were rare
findings in patients with neurologic manifestations of
HIV/AIDS in the United States [2]. In a study from
India [12], cerebral toxoplasmosis was detected in 8.8%
(5/57) which is very low compared to our finding. The
number of patients with presumed diagnosis of primary
CNS lymphoma was very low in our cases probably due
to failure to do brain biopsy when empiric therapy for
toxoplasmosis failed.
Stoke was identified in 2.3% of our patients which is
low compared to a finding in another study [2] which
was 12%. The low number of patients (2%) with
Table 2 Neurologic manifestations of HIV/AIDS in relation to outcome in 347 patients
Diagnosis n(%) Dead(156) n(%) Poor outcome(21) n(%) Improved(170) n(%)
cerebral toxoplasmosis 127(36.6) 56(44.1) 9(7.1) 62(48.8)
Tuberculosis meningitis 78(22.5) 42(53.8) 2(2.6) 34(43.6)
Cryptococcal meningitis 77(22.2) 37(48.1) 3(3.8) 37(48.1)
Bacterial meningitis 24(6.9) 8(33.3) 2(8.3) 14(58.3)
Tuberculoma 10(2.9) 4(40) 1(10) 5(50)
Neurosyphilis 9(2.6) 0 1(11.1) 8(88.9)
Stroke 8(2.3) 3(37.5) 0 5(62.5)
GBS 5(1.4) 1(20) 0 4(80)
Tuberculos spondylitis 5(1.4) 1(20) 2(40) 2(40)
Primary CNS lymphoma 3(0.9) 3(100) 0 0
CIDP 3(0.9) 0 0 3(100)
PML 2(0.6) 1(50) 0 1(50)
Others 3(0.9) 0 2(66.7) 1(33.3)
Note: GBS Guillain-Barre syndrome, CNS central nervous system, CIDP chronic inflammatory demyelinating polyneuropathy, PML progressive multifocal
leukoencephalopathy, Others = pseudotumor cerebri (n = 1), neurocycticercosis (n = 1), HIV-encephalopathy (n = 1). Stroke: ischemic (n = 6), Hemorrhagic (n = 2).
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another study [2] probably shows the limited investiga-
tions available in our set up. Unlike other studies
[2,16,17] HIV-encephalopathy was diagnosed in only
one of our patients (0.28%).
Majority of our patients (89.7%) had a CD4 count
below 200/mm3 which is consistent with another study
[12]. Note that adult healthy Ethiopians have a mean
absolute CD4 T-cell count of 775 cell/μL(range 366-
1,235) in one study [18]. Neuroimaging studies in our
cases showed focal lesions in 56.8% which is higher
when compared to 25.5% obtained in another study [2].
The commonest (80%) cause of mass lesion on imaging
studies in our patients was cerebral toxoplasmosis which
is similar to other studies [1-3,5-7] but contrary to a
study done in South Africa [9] where tuberculosis pre-
dominates as a cause of focal brain lesion(69%). In our
study, normal neuroimaging finding and cerebral atro-
phy were detected in22.7% and 3.9%, respectively which
is lower compared to another study [2]. These might be
explained by the limited access to neuroimaging studies
and the low incidence of HIV-encephalopathy, which is
the main cause of brain atrophy in HIV/AIDS patients,
in our cases. A study [19] on HIV-related neuropathol-
ogy showed that the incidence of HIV-encephalopathy
rises as patients survive longer after initiation of antire-
troviral therapy and is the most common neurologic
complications of HIV/AIDS in such set up [2]. In a
study from Nigeria [10] which included ART naive
patients only, HIV-encephalopathy was found in 12%
(19/154) of cases which is higher when compared to our
study. These show that history of treatment with ART
alone does not explain the low incidence of HIV-ence-
phalopathy in our patients. Our patients were highly
selected group of patients with advanced disease stage
in whom the neurologic symptoms might be oversha-
dowed by overwhelming systemic illness. In addition,
lack of adequate screening techniques and readily avail-
able imaging studies might contribute.
Amphotericin B was not readily available and treat-
ment of cryptococcal meningitis was either Amphoteri-
cin B (n = 32) or oral fluconazole only (n = 45) [There
was no significant difference in mortality, p-value =
0.260]. The limited availability of standard therapy
might explain partly the higher case-fatality of crypto-
coccal meningitis (48.1%) in our cases compared to
32.4% in another study [2]. Sulfadiazine-pyrimethamine
was not available and patients with cerebral toxoplasmo-
sis were treated with pyrimethamin-sulfadoxin. This
might partly explain the higher mortality in our set up
(44.1%) compared to 30.2% in patients who were treated
with standard treatment [2].
The overall hospital mortality was 45% which is high
compared to other studies. In a study done in Nigeria
Table 3 Risk factor for case-fatality: logistic regression analysis
Factor n % Unadjusted
OR(95% CI)
Adjusted
OR(95% CI)
Age(year) < 40 113 44.3 1.00 1.00
≥ 40 43 46.7 1.10(0.684-1.779) 1.033(0.529-2.018)
Sex Male 77 43.8 1.00 1.00
female 79 46.2 1.10(0.723-1.686) 1.033(0.566-1.887)
Address Addis Ababa 133 50.8 1.00 1.00
Outside Addis Ababa 23 27.1 0.360(0.210-0.615) 0.282(0.127-0.630)
History of ART
treatment
Yes 21 38.9 1.00 1.00
No 135 46.1 1.343(0.742-2.430) 1.1(0.506-2.393)
Cotrimoxazole
(prophylaxis)
Yes 8 53.3 1.00 1.00
No 148 44.6 0.704(0.249-1.986) 0.992(0.266-3.705)
Altered sensorium Yes 99 52.9 1.00 1.00
No 57 35.6 0.492(0.319-0.758) 0.514(0.288-0.916)
Seizure Yes 65 54.6 1.00 1.00
No 91 39.9 0.552(0.353-0.863) 0.519(0.288-0.935)
Clinical stage of HIV infection Stage iii 3 20 1.00 1.00
Stage iv 153 46.1 3.419(0.947-12.339) 2.069(0.370-11.562)
CD4 count(/mm
3) < 200 85 42.3 1.00 1.00
≥ 200 6 26.1 0.482(0.182-1.273) 0.572(0.205-1.595)
ART antiretroviral treatment, HIV human immunodeficiency virus CD4 cluster of differentiation 4
Berhe et al. AIDS Research and Therapy 2012, 9:11
http://www.aidsrestherapy.com/content/9/1/11
Page 5 of 7[10] which included outpatients and inpatients, an over-
all 6-month mortality of 45% was found. In another
study from India [11], a mortality of 34% was recorded.
The in-hospital mortality of patients with neurologic
manifestations of AIDS in Brazil [7] was 32%. The case-
fatality for the major neurologic disorders in our study
was: tuberculous meningitis (53.8%), cryptococcal
meningitis (48.1%), cerebral toxoplasmosiss (44.1%) and
bacterial meningitis (33.3%). In a study done in Cambo-
dia [15], the case-fatality rates of tuberculous meningitis
and cryptococcal meningitis was similar to our study
which were 57% and 49%, respectively. In studies done
in South Africa [20] and Nigeria [10] the case-fatality of
HIV associated tuberculous meningitis was 71.8% and
77.5%, respectively, which is higher compared to our
finding.
Both univariate and multivar i a t el o g i s t i cr e g r e s s i o n
analysis showed that address from Addis Ababa, altered
sensorium and seizure were predictors of mortality. The
unexpected relatively lower mortality of patients from
outside the city of Addis Ababa might be partly
explained by selection bias of cases who were relatively
stable and able to travel to the city for better health
care services. History of ART at admission was not
found to improve mortality significantly.
This unexpected finding might be due to the relatively
short period of treatment (mean 7 months, median 5
months), noncompliance (5 patients discontinued ART
and of these 3 died) and only 15.6% of our cases were
on ART. In patients with history of ART the common
neurologic complications identified were: cerebral toxo-
plasmosis (n = 13), cyptococcal meningitis (n = 12),
tuberculous meningitis (n = 10), bacterial meningitis (n
= 9), stroke (n = 4) and others (n = 10). Further study is
recommended to identify other possible reasons for the
failure of ART in our patients.
There were several limitations to this study. Patients
who were treated as outpatient only were not included
and therefore the whole spectrum of neurologic mani-
festation might not be addressed. The absence of certain
neurologic disorders in our study (myelopathy, periph-
eral neuropathy other than inflammatory demyelinating
polyneurpathy, myopathy, etc.) might be partly
explained by inclusion of inpatients only. Our hospital is
a tertiary hospital and the chance of admitting selec-
tively critically sick patients is high due to referral from
other hospitals. The retrospective nature of the study
might have caused unrecoverable missing data in some
cases. There was no autopsy, biopsy, viral load and poly-
merase chain reaction done. CSF glucose and protein
determination was done in minority of patients.
To improve care of patients with neurologic manifes-
tations of HIV/AIDS, early diagnosis of HIV infection,
patient education, starting prophylaxis when needed
(e.g. INH and cotrimoxazole prophylaxis, BCG vaccina-
tion to decrease incidence of tuberculous meningitis),
starting ART timely, making standard therapy for
opportunistic infections readily available(e.g. sulfadia-
zine-pyremethamin with leucovorin and Amphotericin
B), improving availability and quality of laboratory
investigations and neuroimaging studies are very
important.
In conclusion, most of our patients with neurologic
manifestations of HIV/AIDS had advanced disease at
presentations which was evidenced by: almost all were
in stage IV, majority had low CD4 count and most had
opportunistic CNS infections as the leading etiologies.
Majority of patients were diagnosed to have HIV infec-
tion at admission and only a few patients were on ART
and cotrimoxazole prophylaxis. Etiological diagnosis was
difficult in some patients because of limited availability
of laboratory services and lack of facilities for neuroima-
ging studies. Seizure and change in sensorium at presen-
tation were independent predictors of mortality. To
i m p r o v et h eh i g hm o r t a l i t ya n dm o r b i d i t yo b s e r v e di n
our study, prevention of HIV infection, and when it
occurs early diagnosis and appropriate prophylaxis and
treatment of opportunistic infections and timely ART
are recommended.
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